Although GW Pharma (NASDAQ: GWPH) might not be a pot stock in the traditional sense, sales of the company's cannabidiol (CBD)-based drug, Epidiolex, have been growing at an impressive rate. With the company's second CBD-based drug, Nabiximols, set to begin phase 3 trials soon, there's a lot of excitement surrounding GW Pharma right now. Is now the right time to buy GW Pharma? Read More...
Should Investors Buy GW Pharma Stock Right Now?
Although GW Pharma (NASDAQ: GWPH) might not be a pot stock in the traditional sense, sales of the company’s cannabidiol (CBD)-based drug, Epidiolex, have been growing at an impressive rate. With the company’s second CBD-based drug, Nabiximols, set to begin phase 3 trials soon, there’s a lot of excitement surrounding GW Pharma right now. Is now the right time to buy GW Pharma?
Add Comment